Novalis Biotechnology Incubation

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Alithea Genomics, based in Switzerland, specializes in RNA sequencing and transcriptomics to support biomedical discoveries. The company employs proprietary technology to enhance the efficiency and cost-effectiveness of Ribonucleic acid sequencing, significantly increasing the throughput of analyzed samples. With expertise in bioengineering, molecular biology, and genomics, Alithea Genomics aims to facilitate pharmaceutical companies in their research efforts, ultimately advancing the field of biomedical research.

Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.

Rarity Bioscience specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences in biological samples, particularly in liquid biopsies. The company offers an ultrasensitive multiplex assay that enables the identification of rare DNA sequence variants. This innovative platform serves both research and clinical applications, providing physicians with valuable tools for accurate diagnostics and improved patient care.

C-mo Medical Solutions specializes in developing monitoring devices aimed at providing a comprehensive assessment of cough patterns in patients. The company's portable and ergonomic wearables facilitate long monitoring periods and the detection of distinctive cough patterns. With fully automated analysis capabilities, these devices enable healthcare professionals to deliver accurate diagnoses and prescribe personalized treatment plans. By addressing key use-cases throughout the patient management lifecycle, C-mo Medical Solutions plays a significant role in enhancing cough-related healthcare.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Carroucell specializes in providing microcarriers for cell culture in bioreactors. The company has developed a unique microscopic matrices platform that features flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing processes by addressing common performance challenges associated with traditional cell culture methods. Carroucell's products are tailored to meet the needs of customers in the biopharmaceutical industry, facilitating improved outcomes in cell culture applications.

Alithea Genomics, based in Switzerland, specializes in RNA sequencing and transcriptomics to support biomedical discoveries. The company employs proprietary technology to enhance the efficiency and cost-effectiveness of Ribonucleic acid sequencing, significantly increasing the throughput of analyzed samples. With expertise in bioengineering, molecular biology, and genomics, Alithea Genomics aims to facilitate pharmaceutical companies in their research efforts, ultimately advancing the field of biomedical research.

Trince is a company focused on advancing cell-based science and therapeutics through innovative cell transfection technology. It specializes in facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's platform utilizes a combination of laser exposure and photothermal nanoparticles, which convert light energy into heat to temporarily permeabilize the cellular plasma membrane. This process enables high-throughput introduction of genetic material into cells, thereby assisting clients in their research and development efforts in the field of molecular biology.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

RheaVita is a pharmaceutical company that specializes in advanced continuous freeze-drying technology for biopharmaceutical products. This innovative technology integrates all steps of the freeze-drying process into a continuous production line, allowing for the constant infeed of products and simultaneous outfeed of dried goods. By improving the manufacturing process, RheaVita's approach addresses the limitations of traditional batch freeze-drying, significantly reducing processing times and minimizing scale-up challenges. The company’s method not only lowers production costs and requires smaller manufacturing facilities with less clean room space, but it also enhances quality assurance through comprehensive inspection and the potential for real-time release. Overall, RheaVita's technology results in improved and consistent product quality, contributing to faster development and reduced time-to-market for pharmaceutical medicines.

Grapheal is a Medtech startup focused on developing embedded and wearable biosensors that leverage graphene transistors for enhanced functionality. Their devices are designed to be minimalistic and digital, enabling the dosing of biomarkers and detection of pathogens through a smartphone interface. By integrating advanced sensing nanomaterials with wireless connectivity and data analysis capabilities, Grapheal's biosensors facilitate field diagnostics and remote patient monitoring. This approach aims to make healthcare more accessible and accurate, allowing medical professionals to effectively monitor patient progress and healing.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.